Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Combined Mass Spectrometry System

By Drug Discovery Trends Editor | June 8, 2009

BioTrove, Inc. presented data at the 57th American Society for Mass Spectrometry Conference on Mass Spectrometry in Philadelphia, Pennsylvania demonstrating the compatibility of its RapidFire Mass Spectrometry (RF-MS) system with Agilent Technologies Inc.’s Time-of-Flight (TOF) mass spectrometer system for high-throughput screening of protein inhibitors and examination of drug-drug interaction assays. Combining the two platforms, drug discovery researchers can now perform high-throughput drug-drug interaction and label-free kinase assays using whole protein substrates.

These data were presented by Drs. William A. LaMarr and Michelle V. Romm. Dr. LaMarr showed that the RapidFire/Time-of-Flight system provides researchers accurate mass data for high-throughput analysis of CYP inhibition assays. The use of accurate mass measurements afforded by the Agilent TOF-MS has the potential to streamline the workflow in other in vitro ADME applications such as metabolic stability assays by eliminating the bottleneck of MS method development.

Dr. Romm’s presentation demonstrated that the RapidFire/Time-of-Flight system provides a high-throughput screening interface for the label-free detection of whole protein kinase activity at per sample throughputs under 10 seconds. The ability to use whole protein substrates in kinase assays enables researchers to investigate challenging kinase targets, such as those that have multiple phosphorylation sites or kinases that auto-phosphorylate, that are problematic to study with optical or radiometric assay formats.

The integration of RapidFire with Agilent’s state-of-the-art Time-of-Flight technology provides scientists a new tool to accelerate and expand on possibilities in drug discovery and disease research. These combined technologies provide scientists an end-to-end solution for high-throughput drug discovery and ADME screening.

The RapidFire/Time-of-Flight system allows for the analysis of whole proteins in their native state, rather than fragmented peptide substrates, including methylases and demethylases, ubiquitinases, acetylases and deacetylases, kinases, and phosphatases.

Source: Biotrove 


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE